American Society for Clinical Oncology abstracts were released today. Meeting is June 1-5 in Chicago. Not too much on the bromodomain/BET inhibitor front. I see that Abbvie has 5 bromodomain/BET abstracts (4 on their pan-BETi ABBV-075), but nothing ground breaking. Phase 1 safety/dose finding studies in solid, melanoma and hematological. But the only other BETi abstract is a Phase 1 safety/dose finding study for PLX51107 from Plexxikon Inc. You can search up these abstracts yourself at this link and search "BET":
Still a chance for a Zenith late-breaking abstract, based on what I understand in the ASCO policy:
"Note: Only those abstracts selected for release on site at the 2018 ASCO Annual Meeting will be designated as late-breaking abstracts (LBAs), including Plenary abstracts.
Late-breaking abstracts (LBAs) will be publicly released on a rolling basis throughout the 2018 ASCO Annual Meeting. The complete embargo dates and public release schedule for LBAs are detailed below.
All other abstracts, including those submitted during the late-breaking submission time period but not selected as late-breaking abstracts, will be publicly released at 5:00 p.m. ET on May 16, 2018, and available online."
On a side note, it seems that the official stem/suffix terminology for clinical BET inhibitors is "-bresib." So far I've seen Birabresib (OTX-015) and Mivebresib (ABBV-075). I'm sure we'll be hearing about more BET inhibitors being named with this official nomenclature. Zenebresib?
BDAZ
